Professional experience
Since 2006, he has been Head of the Neurology Department at the Quironsalud University Hospital of Madrid and the Ruber Juan Bravo Hospital.
Professor of Medicine at the Faculty of Biomedical Sciences of the European University of Madrid, holds the national accreditation of Professor of Medical Sciences (issued by ANECA).
Doctor of Medicine, Complutense University of Madrid (UCM). Award for Outstanding Doctoral Thesis (UCM, 2004): Study on the relationship of human herpes virus 6 as an environmental factor in multiple sclerosis.
Membership in scientific societies
National and International Principal Investigator in Neuroscience at Quironsalud Madrid (June 2015 – present)
President of the Research Committee of the Quironsalud University Hospital of Madrid (2012 to present).
Member of the Research Committee of the San Carlos Clinical Hospital (2012-2015).
Member of the Council of the Faculty of Medicine of the Complutense University of Madrid (2011-2015).
Research and Teaching
Principal investigator of 100 national and international clinical trials.
7 FIS research projects from the Carlos III Institute of Health (the last 5 as principal investigator).
10 projects from private foundations, received on a competitive basis (7 as principal investigator).
He has authored 139 international articles with a total impact factor of 949,917 and 4,552 citations. 38 books and book chapters with an H-factor of 34 (2018).
His publications stand out in journals that have the greatest global impact on research, such as the New England Journal of Medicine and the Lancet.
Dr. Rafael Arroyo has given over 300 international and national presentations at various Congresses.
Education :
Professor of Medicine at the Faculty of Biomedical Sciences of the European University of Madrid and holds the national accreditation of Professor of Medical Sciences (issued by ANECA).
Pathologies
-Benign brain tumors: meningiomas and neuromas:
-Cerebral vascular malformations:
-Obsessive-compulsive disorder treatment operations:
-Operations to combat nervous anorexia:
Publications
2023 | Stereotactic radiosurgery for Kuss grade IV vestibular schwannoma in patients ≥ 65 years: a multi-institutional retrospective study Acta Neurochirurgica 165: 211–220,
2022 | Stereotactic radiosurgery for Kues grade IV vestibular schwannoma in young patients: a multi-institutional study Journal of Neuro-Oncology 160: 201–208.
2022 | Stereotactic radiosurgery versus active surveillance for asymptomatic, parafalcine, and parasagittal meningiomas: a matched cohort analysis from the IMPASSE Neurosurgery 90:750–757
2022| Active surveillance versus stereotactic radiosurgery for the treatment of patients with incident frontobasal meningioma - A subanalysis of the IMPASSE Cancers (Basel) trial. Mar 3;14(5):1300.
2022| Gamma Knife Outcomes and Recommendations and Complications: Patai fond Kuala Lumpur
2022| Radiosurgery for Mental Disorders LGKA Marsella
2022| The Role of SRS in Anorexia Nervosa ISRS Milan
2022| Expanding the indications for gamma knife radiosurgery Neuroonc and Rs Symp Malasia
2022 | Pituitary Adenoma: Conservative in Surgical Abortion Simp CUF Lisbo
Awards and certificates
2019|National Medical Prize XXI in the field of neurosurgery.
2018 | Editorial Board Member, American Journal of Psychiatry and Neurology
2015 | Factory Award torn away from the International Society of Stereotactic and Radiosurgery
2012 | Correspondent of the Real Medical Academy of Asturias.
Since 1998 he has been Director of the Epilepsy Unit at the Ruber International Hospital in Madrid, a pioneering centre for the diagnosis, medical and surgical treatment of epilepsy in children and adults.
More than 150 neurologists and neurophysiologists from Spain and Latin America have been trained here, and several of its students have successfully opened epilepsy centres in other public and private hospitals, both in Spain and abroad.
The program he directs has become a pioneer in Spain in the field of genetic diagnosis of complex epilepsies and advanced treatments such as drug repositioning, interstitial laser treatment, deep electrodes and gamma radiosurgery, which are used in patients with refractory epilepsy.
Dr. Antonio Gil-Nagel is a professor at the IE University, is an Ad Honorem Professor at the Center for Biomedical Technology of the Polytechnic University of Madrid (CTB) and is Director of the Epilepsy Department at the Francisco Vitoria University of Madrid.
He was a founding member of the European Epilepsy Research Network and the European Association for Epilepsy Monitoring. He is also active in international research projects such as EpiCare and the European Epilepsy Brain Bank and has held relevant positions in international institutions such as the International Bureau for Epilepsy (IBE), the International League Against Epilepsy (ILAE), the European Federation of Neurological Societies (EFNS) and the World Federation of Neurology (WFN).
Dr. Gil-Nagel has directed numerous clinical trials and research studies in the field of epilepsy, especially in orphan epilepsies such as Dravet syndrome, Lennox-Gastaut syndrome and other epileptic and developmental encephalopathies. The Epilepsy Program he directs is an international benchmark in the development of pharmacological research. He has been the Principal Investigator of phase II and III clinical trials, including numerous clinical trials and non-pharmacological treatments (epilepsy surgery, electrical stimulation, ketogenic diet and gamma knife). His research is funded by European Union funds and the Public Innovation Agency of the Ministry of Science and Innovation of the Spanish Government. Their dedication to research and the development of new treatments allows them to accelerate the treatment of their patients with new treatments.
In addition to being a frequent speaker at national and international conferences, he has authored several books on epilepsy and electroencephalography and has numerous publications on epilepsy in journals such as Annals of Neurology, Brain, Epilepsy, European Journal of Neurology, Journal of Neurology, Nature Neurology, Neurology, and the New England Journal of Medicine, among others. He has authored 165 Scopus-indexed articles with 5,265 citations and an h-index of 35.
In 2021, his team received the Innovative Small and Medium Enterprise Award for the project on mesial temporal lobe epilepsy and encephalocele (Ministry of Science and Innovation, Spain), and in 2012, the Scientific Award from the Epilepsy Group of the Spanish Society of Neurology (SEN).
Dr. Hill-Nagel is a leading international figure in the field of epileptology, a recognized expert in the diagnosis and treatment of genetic epilepsy and the surgical approach to its correction. His distinguished professional career includes many years of experience in leading medical institutions in the United States and Europe, as well as active participation in international research and educational programs.
Dr. Hill-Nagel not only advances the science of neurology on a global level, but also successfully implements cutting-edge treatment methods, improving the lives of thousands of patients around the world.